🧠 Module 31: Crohn’s Disease and COVID-19 Risk
Crohn’s disease is a long-term inflammatory bowel disease (IBD) that affects the digestive system.
🧬 Key Finding (2026)
- Crohn’s disease does NOT usually increase the risk of catching COVID-19
- Most people with Crohn’s have similar COVID-19 risk to the general population
⚠️ When Risk May Increase
Risk of more severe COVID-19 may be higher if:
- Disease is in an active flare-up
- Patient is on steroid medication (e.g. prednisone)
- Patient has other health conditions or is older
- Patient is on strong immunosuppressants
💊 Medication Considerations
- Do NOT stop Crohn’s medication without medical advice
- Keeping Crohn’s in remission reduces overall risk
- Biologics and immune therapies are usually continued under supervision
🛡️ Vaccination
- Strongly recommended for all Crohn’s patients
- May be slightly less effective if on immunosuppressants
- Still provides important protection against severe illness
🦠 Module 32: COVID-19 in Crohn’s Patients
COVID-19 affects Crohn’s patients in similar ways to the general population, but with some extra considerations.
📌 Symptoms (General + IBD context)
- Fever
- Cough
- Fatigue
- Shortness of breath
- Possible increased diarrhoea or gut symptoms
⚠️ Risk Factors for Severe Illness
- Active Crohn’s flare
- Steroid use
- Older age
- Other long-term health conditions
- Multiple immunosuppressive therapies
💊 Treatment Considerations
- Antiviral medication (e.g. Paxlovid) may be used in eligible patients
- Treatment plans should be adjusted by healthcare professionals
- Hospital care may be required in severe cases
🧠 Key Message
- Crohn’s patients should continue treatment
- Disease control is important for reducing complications
- Medical advice should always be followed during infection
📊 Summary Table (Modules 31–32)
| Module | Focus | Key Idea |
|---|---|---|
| 31 | Crohn’s & COVID risk | Risk depends on disease activity + medication |
| 32 | COVID-19 effects | Similar symptoms, but higher risk in flare/immunosuppression |
No comments:
Post a Comment